Aliskiren for heart failure: a systematic review and meta-analysis of randomized controlled trials.
Conclusions: Aliskiren, either used alone or combined with standard medical therapy, does not significantly reduce the all-cause mortality or cardiovascular mortality of heart failure patients. Although aliskiren does not cause statistically higher adverse events, its adverse events may not be neglected.
PMID: 29152151 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cardiology | Cardiovascular | Databases & Libraries | Heart | Heart Failure | Statistics | Study | Tekturna